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Abstract This study evaluated the efficacy of percuta-
neous radiofrequency ablation (RFA) for the treatment of
metachronous liver metastases of gastric cancer. We
enrolled a total of 44 patients who underwent percutaneous
RFA for the treatment of metachronous liver metastases
after resection of a primary gastric adenocarcinoma from
January 2002 to November 2011. The primary endpoint of
this study was overall survival (OS) and recurrence-free
survival (RFS) after RFA. Systemic chemotherapy was
combined with RFA in 40 patients; the OS and RFS of the
patients with liver-only metastasis who underwent RFA
and chemotherapy were 20.9 months (95 % CI 18.4–23.4)
and 9.8 months (95 % CI 9.2–10.5), respectively. On
multivariate analysis, the factors independently, negatively
associated with OS were extrahepatic metastatic lesions
(HR 12.6, 95 % CI 3.7–42.9; p = 0.001), no chemotherapy
(HR 43.3, 95 % CI 7.4–251.3; p = 0.001), and tumor
number C2 (HR 2.6, 95 % CI 1.2–5.9; p = 0.015). The
factors independently, negatively associated with RFS
were extrahepatic metastatic lesions (HR 3.6, 95 % CI
1.6–7.8; p = 0.003) and bilobar intrahepatic distribution
(HR 3.9, 95 % CI 1.5–9.9; p = 0.001). The efficacy of
percutaneous RFA for metachronous liver metastases of
gastric cancer is limited to patients with a single, unilobar
metastasis without extrahepatic metastatic lesions. Com-
bined systemic chemotherapy is very important for the
prolongation of OS.
Keywords Radiofrequency ablation  Stomach
neoplasms  Metastasis  Chemotherapy
Introduction
Liver metastasis from gastric cancer (LMGC) has a very
poor prognosis and there are no effective treatment
modalities [1]. Liver metastases can be found in 5–9 % of
patients with gastric cancer, and cancer recurrence and
metastatic patterns are associated with locoregional, peri-
toneal, and hematogenous metastases; all metastatic pat-
terns are found simultaneously in most cases [2–4]. The
vast majority of patients with LMGC may in fact have
systemic disease. Only a very small subset of patients with
LMGC are candidates for surgical resection as the disease
is often associated with extrahepatic metastatic lesions:
peritoneal dissemination, lymph node metastases, and
direct cancer invasion of other organs [1, 4, 5].
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The benefits of surgical resection for LMGC are unsat-
isfactory; systemic chemotherapy is a standard treatment
approach for most patients with this disease [1, 6, 7].
Radiofrequency ablation (RFA) is a commonly-used
alternative to surgery for tumor ablation [8]. The treatment
efficacy of RFA for LMGC, however, remains poorly
defined. In this study, we evaluated the efficacy of percu-
taneous RFA for treatment of metachronous liver metas-




At Chonnam National University Hwasun Hospital in
Jeonnam, Korea, a total of 1,342 patients with recurrent or
metastatic gastric cancer received palliative chemotherapy
between January 2002 and November 2011. The criteria for
inclusion in our study of RFA for liver metastases were as
follows: (1) histologically confirmed gastric adenocarci-
noma; (2) presence of metachronous liver metastases,
arising more than 3 months after surgery; (3) percutaneous
complete ablation of the liver metastases was feasible; (4)
no evidence of anastomotic site recurrence; (5) absence of
extrahepatic metastatic lesions (preferable), or presence of
minimal extrahepatic metastatic lesions with liver metas-
tases considered suitable for RFA. Of the original 1,342
patients, a total of 229 (17 %) had liver metastases. Of
these 229 patients, 185 were not considered eligible for
RFA due to tumor growth in multiple liver segments,
extensive extrahepatic metastatic lesions, and/or unfavor-
able clinical conditions such as poor performance status,
old age, and cardiopulmonary dysfunction. We prospec-
tively enrolled a total of 44 patients to undergo RFA for the
treatment of metachronous liver metastasis after curative
margin-negative (R0) resection of the primary gastric
adenocarcinoma. All data were prospectively recorded and
only the survival data was updated from the cancer registry
at the time of analyses. Eastern Cooperative Oncology
Group performance status (ECOG PS) was evaluated
according to the established criteria. This study was
approved by the Institutional Review Board of Chonnam
National University Medical School Research Institution
(2012-110). The recommendations of the Declaration of
Helsinki for biomedical research involving human subjects
were followed throughout.
Liver metastases were diagnosed during a pre-pro-
grammed follow-up schedule of physical examination,
simple chest radiography, abdomal computed tomography
(CT), endoscopy, and, if necessary, liver magnetic reso-
nance imaging (MRI). Chest CT and bone scan or positron
emission tomography were performed to evaluate for
extrahepatic metastatic lesions if liver metastases were
detected. A total of five patients received a needle aspira-
tion biopsy just before RFA, as their abdominal CT and
MRI scans did not show the typical enhancement pattern of
liver metastases. All biopsy results demonstrated metastatic
adenocarcinoma.
RFA technique
Percutaneous hepatic lesion RFA was performed, under
local and intravenous anesthesia, by two experienced
interventional radiologists with 14 and 6 years of experi-
ence, respectively. RFA was performed using an internally-
cooled monopolar electrode with a 3 cm active tip (Val-
leylab, Boulder, CO, USA) and a 150 W radiofrequency
generator (Cool-tip RF System, Radionics, Burlington,
MA, USA). A standard grounding pad (Valleylab, Boulder,
CO, USA) was placed on the patient’s back. All RFA was
performed under real-time sonographic guidance with a
1–5 MHz curved probe (LOGIQ E9, GE Healthcare, Mil-
waukee, WI, USA). Radiofrequency current was applied to
each lesion for 12 min at 150 W to create a radius of
ablation at least 10 mm larger than the largest tumor
diameter. If the tumors were larger than 2.5 cm in greatest
diameter, we performed multiple overlapping ablations to
cover the entire tumor, with a 5 mm ablative margin. After
RFA, the intrahepatic electrode track was cauterized to
minimize bleeding and prevent tumoral seeding.
One hour after the initial treatment, contrast-enhanced
dynamic CT was performed. When the thickness of the
ablative margin was at least 0.5 cm for the index tumor, the
treatment was considered finished. When a residual
enhanced lesion was seen on dynamic CT, an additional
RFA was immediately performed.
Follow-up
Local therapeutic and technical efficacy was evaluated by
contrast-enhanced dynamic CT scanning 1 month after
RFA. Clinical tumor recurrence and response was assessed
according to the Response Evaluation Criteria in Solid
Tumors (RECIST version 1.0) [9], by subsequent CT
scanning after every two or three courses of chemotherapy.
When patients did not receive chemotherapy, CT scanning
was performed every 3 months after RFA, or in the case of
clinical suspicion for recurrence.
Chemotherapy
Peri-procedural systemic chemotherapy was administered
to patients just before (n = 23) or after (n = 17) RFA
(within 3 weeks before or after RFA). In patients with no
26 Clin Exp Metastasis (2014) 31:25–32
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evidence of recurrence, chemotherapy was maintained for
6 months. When follow-up CT showed intrahepatic or
extrahepatic recurrence, second-line chemotherapy was
initiated or best supportive care was performed, according
to the clinical situation. Chemotherapy regimens included a
variety of agents such as taxanes, oxaliplatin, irinotecan,
cisplatin, 5-fluorouracil (5-FU), and TS-1. Doublet che-
motherapy regimens were most commonly used.
Statistics
Kaplan–Meier analysis was applied to assess clinical fac-
tors affecting overall survival (OS) and recurrence-free
survival (RFS), and the significance of differences in sur-
vival curves was determined by the log-rank test. OS was
defined as the period from the date of RFA to the date of
death from any cause. RFS was defined as the period from
the date of RFA to the date of disease progression or death,
whichever occurred first. If neither event had occurred at
the time of the last record, the patient was censored at that
time. The factors included in univariate survival analysis
were age, gender, ECOG PS, tumor size, tumor number,
presence of liver-only metastases, presence of extrahepatic
metastatic lesions, and intrahepatic tumor distribution
(unilobar or bilobar). Multivariate regression analysis using
the Cox proportional hazards regression model (stepwise
forward procedure), was performed to achieve an adjusted
hazard ratio (HR) to determine the prognostic factors for
OS and RFS. A 2-tailed p \ 0.05 was considered signifi-
cant for all analysis. The SPSS software package, version




The baseline characteristics of the 44 patients are listed in
Table 1. All patients had gastric adenocarcinoma and there
were no distant metastases identified at the time of initial
operation. All patients received curative resection for their
gastric cancer, combined with D2 lymph node dissection.
The median follow-up time (from surgery to death or last
follow-up date) was 31.7 months, with a range of
10.5–57.1 months. The median patient age was 64 years,
with a range of 38–83 years. A total of 26 patients
(59.1 %) were male, and 18 patients (40.9 %) were female.
The median time to development of liver metastases after
surgery was 12.9 months (95 % CI 3.9–37.7 months). A
total of 13 patients (29.5 %) had simultaneous extrahepatic
metastatic lesions: 11 patients (25 %) had metastases to
intraabdominal lymph nodes; 1 patient had peritoneal
seeding nodules; one patient had a metastatic pleural
nodule. A total of 30 patients (68.2 %) had a unilobar
intrahepatic distribution, and 14 patients (31.8 %) had
bilobar intrahepatic metastatic tumors. A total of 23
patients had a single liver metastasis, 20 patients had 2
liver metastatic tumors, and only 1 patient had 3 liver
metastases. The median size of the largest metastatic liver
tumor was 2 cm, with a range of 1–2.7 cm. A total of 40
patients (90.9 %) received systemic chemotherapy, and 18
patients (41 %) received second-line chemotherapy. Only
four patients did not receive systemic chemotherapy due to
patient’s refusal; these patients had liver-only metastases.
All patients with extrahepatic metastatic lesions received
chemotherapy. The most commonly used chemotherapy
regimen was a oxaliplatin and 5-FU doublet (n = 16,
40 %). The specific chemotherapy regimens are shown in
Table 2.
Table 1 Patient characteristics (n = 44)
Characteristics Number of patients (n = 44)
Age (years)



















No extrahepatic disease 31






ECOG PS Eastern Cooperative Oncology Group performance status
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Results of RFA
Radiofrequency ablation was technically successful for all
tumors. A total of 42 patients showed complete disap-
pearance of tumor enhancement in the contrast-enhanced
CT acquired 1 h after treatment. Two patients with small
residual tumors underwent immediate additional RFA.
There were no significant adverse events. Almost all
patients demonstrated mild to moderate abdominal pain
and liver enzyme elevations. Both the abdominal pain and
liver enzyme elevations resolved with supportive care. A
total of three patients suffered from transient Gram-nega-
tive bacteremia. These patients were treated with antibi-
otics: two patients were treated with a third generation
cephalosporin, one with a carbapenem. All three recovered
without sequelae.
Survival and prognostic factors
The median OS after RFA in all patients was 14.7 months
(95 % CI 10.1–19.2). The median RFS after RFA in all
patients was 6.1 months (95 % CI 4.2–8.1). The median
OS and RFS of patients with liver-only metastases who
underwent RFA and chemotherapy were 20.9 months
(95 % CI 18.4–23.4) and 9.8 months (95 % CI 9.2–10.5),
respectively. The median OS and RFS of patients with
extrahepatic metastatic lesions who underwent RFA and
chemotherapy were only 11.2 months (95 % CI 9.8–12.5)
and 4.3 months (95 % CI 3.8–4.9), respectively. Patients
with liver-only metastases who underwent RFA and che-
motherapy had a better median OS and RFS than patients
with extrahepatic metastatic lesions who underwent the
same treatment. The difference was statistically significant
(Table 3) (Figs. 1, 2).
In our study, in spite of the small number of patients
(n = 4), patients who did not receive chemotherapy had
significantly shorter OS compared with patients receiving
chemotherapy (n = 40) [8.1 months (95 % CI 7.6–8.6) vs.
16.7 months (95 % CI 12.0–21.4)]. A total of 18 patients
received second-line chemotherapy, however second-line
chemotherapy did not affect OS [second-line chemother-
apy (?) vs. (-), 18.0 vs. 14.7 months, p = 0.203].
In univariate analysis, the OS after RFA was signifi-
cantly shorter for patients with the following clinical fac-
tors: no systemic chemotherapy, the presence of
extrahepatic metastatic lesions, C2 liver metastases, and
bilobar intrahepatic distribution. Univariate analysis also
demonstrated that the presence of extrahepatic metastatic
lesions, C2 liver metastases, and bilobar intrahepatic dis-
tribution were significantly associated with a shorter RFS
after RFA (Table 4).
Multivariate regression analysis identified the indepen-
dent negative prognostic factors for OS and RFS (Table 5).
The independent negative prognostic factors for OS were
the presence of extrahepatic metastatic lesions (HR 12.6,
95 % CI 3.7–42.9; p = 0.001), C2 liver metastases (HR
2.6, 95 % CI 1.2–5.9; p = 0.015), and no systemic che-
motherapy (HR 43.3, 95 % CI 7.4–251.3; p = 0.001). The
independent negative prognostic factors for RFS were the
presence of extrahepatic metastatic lesions (HR 3.6, 95 %
CI 1.6–7.8; p = 0.003), and intrahepatic bilobar distribu-
tion (HR 3.9, 95 % CI 1.5–9.9; p = 0.001).
Discussion
Recurrent or metastatic gastric cancer, including the pres-
ence of liver metastases has a very poor prognosis, and
most oncologists recommend systemic chemotherapy.
According to recent reports, the median OS of patients
treated with combination chemotherapy, with or without a
targeted agent such as trastuzumab, is about 13 months [6,
10, 11].
Liver resection for metastatic tumors is performed
mainly in patients with primary colorectal cancer, with
resection rates of 20–30 % and a 5-year survival rate of
25–85 % [12, 13]. In contrast, liver resection for LMGC is
a rarely-performed procedure. The rate of hepatic resection
in LMGC ranges from only 0.5 to 2.3 % [2, 14]. Most
patients with LMGC remain incurable due to bilobar,
multinodular tumor spread, gross peritoneal dissemination,
diffuse metastases to distant lymph nodes, or unresectable
local recurrences [4, 15–17]. In a recently published
review, 19 studies were analyzed to compare survival
periods following hepatic resection for LMGC. The median
survival for all 436 patients was 17 months, and the 5-year
survival was 26.5 % [18]. Several authors have reported
better OS in patients with metachronous liver metastasis
than in those with synchronous disease after hepatic
resection [19–21]. Ambiru et al. [21] reported significantly
longer survival in patients with metachronous metastasis
(5-year survival 29 %) than in those with synchronous
disease (5-year survival 6 %). However, Sakamoto et al.
[2] reported no significant difference in survival between
synchronous and metachronous metastasis after hepatic
Table 2 Chemotherapy regimens (n = 40)




Weekly paclitaxel 2 5
TS-1 2 5
Total 40 100
28 Clin Exp Metastasis (2014) 31:25–32
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resection (19.2 vs. 21.4 months, p = 0.84). In our study,
we found a median OS of 20.9 months for those patients
who underwent RFA and chemotherapy for liver-only
metastases; this is comparable to the results for surgical
resection.
After detecting a liver recurrence, oncologists have to be
extremely cautious about patient selection for surgical
resection, so as to avoid an inadequate or extensive oper-
ation in a high-risk patient whose disease is incurable by
resection. Sakamoto et al. [1] reported that unilobar
metastases and/or a tumor \4 cm in diameter may be
indications for surgical resection. The number of liver
metastases can be another significant prognostic factor.
Gannon et al. [22] reported that, from a tumor biology and
behavior perspective, RFA would not be effective for more
than five metastases. Shirabe et al. [23] also reported that
the presence of more than three liver metastases was an
independent poor prognostic factor, based on observations
in patients after liver resection of LMGC. In our study, the
independent negative prognostic factors for OS were
presence of extrahepatic metastatic lesions, number of liver
metastases (C2), and no systemic chemotherapy.
Recurrent liver tumors are common after curative
hepatic resection for gastric metastases, occurring in about
two-thirds of patients [7, 24]. This high recurrence rate
might suggest the presence of occult intrahepatic metas-
tases, even at the time of the hepatectomy [1]. In our study,
a total of 27 patients (61.4 %) developed intrahepatic
recurrence after RFA.
The efficacy of adjuvant chemotherapy after liver
resection of LMGC has not been fully evaluated [25, 26].
Chemotherapy after liver resection of LMGC may be
beneficial in terms of the high risk of recurrence, and the
same may apply to RFA. In our study, in spite of the small
Table 3 Patients with liver-only metastases who underwent radiofrequency ablation and chemotherapy had a better median overall survival and
recurrence-free survival than patients with extrahepatic metastatic lesion who underwent the same treatment (statistically significant)
Liver-only metastasis with RFA
and chemotherapy (n = 27)
Liver and extrahepatic disease with
RFA and chemotherapy (n = 13)
p value
mOS (months) 20.9 11.2 0.001
(95 % CI 18.4–23.4) (95 % CI 9.8–12.5)
mRFS (months) 9.8 4.3 0.001
(95 % CI 9.2–10.5) (95 % CI 3.8–4.9)
mOS median overall survival, mRFS median recurrence-free survival, RFA radiofrequency ablation
Fig. 1 Overall survival curve for patients with liver-only metastases
who underwent radiofrequency ablation and chemotherapy (blue line)
and patients with extrahepatic metastatic lesion who underwent the
same treatment (green line). (Color figure online)
Fig. 2 Recurrence-free survival curve for patients with liver-only
metastases who underwent radiofrequency ablation and chemotherapy
(blue line) and patients with extrahepatic metastatic lesion who
underwent the same treatment (green line). (Color figure online)
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number of patients (n = 4) who did not receive chemo-
therapy, these patients had significantly shorter OS com-
pared with those who did undergo chemotherapy.
In Korea, it has been common practice for patients who
fail first-line palliative chemotherapy to receive second-
line chemotherapy and Kang et al. [27] reported that sal-
vage chemotherapy (second- or third-line chemotherapy) in
advanced gastric cancer resulted in significant prolongation
of survival when compared with best supportive care. In
our study, second-line chemotherapy did not affect OS. We
propose that this was due to the small number of patients of
this study.
Radiofrequency ablation has been used for the treatment
of primary and secondary hepatic malignancies,
Table 4 Univariate analysis of clinical factors influencing median overall survival and median recurrence-free survival (n = 44)
Clinical factors mOS mRFS
Months (95 % CI) p value Months (95 % CI) p value
Age (years)
\64 13.1 (7.1–19.1) 0.473 5.9 (4.4–7.3) 0.642
C64 18.0 (9.0–26.9) 7.4 (3.0–11.8)
Gender
Male 13.1 (11.1–15.0) 0.827 7.3 (4.8–9.7) 0.269
Female 16.1 (12.1–20.2) 6.0 (0.7–11.3)
ECOG PS
0 13.8 (11.3–16.3) 0.761 7.3 (4.2–10.3) 0.504
1 17.1 (7.6–26.6) 5.9 (4.5–7.2)
Primary tumor pathologic stage
II 16.1 (9.9–22.4) 0.602 7.3 (4.2–10.4) 0.464
III 14.7 (8.8–20.5) 6.0 (2.5–9.4)
Histologic grade
Well differentiated 13.8 (9.0–18.7) 0.811 5.9 (3.2–8.5) 0.925
Poorly differentiated 20.6 (11.3–29.8) 9.4 (5.7–13.0)
Chemotherapy
Yes 16.7 (12.0–21.4) 0.001 7.4 (3.5–11.3) 0.379
No 8.1 (7.6–8.6) 5.4 (2.5–8.3)
Tumor size
\2 cm 16.1 (5.8–26.4) 0.187 7.4 (2.8–1.9) 0.297
C2 cm 13.1 (7.6–18.6) 5.9 (2.3–9.5)
Tumor number
1 20.9 (11.4–30.3) 0.006 9.9 (8.1–11.7) 0.005
C2 11.8 (8.9–14.6) 4.6 (3.5–5.7)
Extrahepatic metastatic lesion
No (liver-only metastasis) 19.6 (14.5–24.7) 0.001 9.5 (7.9–11.0) 0.001
Yes 11.2 (9.8–12.5) 4.3 (3.8–4.9)
Intrahepatic distribution
Unilobar 20.9 (13.9–27.9) 0.001 9.8 (9.1–10.6) 0.001
Bilobar 11.2 (8.6–13.7) 4.1 (3.5–4.7)
mOS median overall survival, mRFS median recurrence-free survival, ECOG PS Eastern Cooperative Oncology Group performance status
Table 5 Multivariate analysis of factors influencing overall survival
and recurrence-free survival




Extrahepatic metastatic lesion 12.6 (3.7–42.9) 0.001
Number of liver metastasis (C2) 2.6 (1.2–5.9) 0.015
No chemotherapy 43.3 (7.4–251.3) 0.001
RFS




OS overall survival, RFS recurrence-free survival
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particularly in hepatocellular carcinoma and colorectal
cancer, and its use is steadily increasing. Compared with
hepatic resection, RFA is relatively less invasive, resulting
in fewer complications, a lower mortality rate, a shorter
hospital stay, and a lower treatment cost [8, 28]. The role of
RFA in LMGC is not clearly defined. Several reports have
demonstrated the beneficial local control effect of RFA and
the potential additional benefit of chemotherapy, however,
these reports featured a very small and heterogeneous
patient population [14, 25, 29].
Considering the high recurrence rate of this disease and
the early clinical recovery after RFA compared with sur-
gery, the combined treatment of systemic chemotherapy
and RFA may be a potential therapeutic strategy for
metachronous liver metastases after resection of the pri-
mary gastric cancer. More early administration of chemo-
therapy may be possible after RFA rather than after
surgery.
Conclusion
Combination of percutaneous RFA and systemic chemo-
therapy may be effective treatment modalities for patients
with a single, unilobar metachronous LMGC without
extrahepatic metastatic disease.
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